Longitudinal analysis of adiponectin to leptin and apolipoprotein B to A1 ratios as markers of future airflow obstruction and lung function decline Authors: Seohyun Kim, Chin Kook Rhee, Yong Suk Jo, Jeong Uk Lim, Sang Hyuk Kim, Jaeeun Yoo, Joon Young Choi Published: 2024 ABSTRACT Previous studies suggest associations between the risk of developing chronic obstructive pulmonary disease (COPD) and adiponectin/leptin (ALR) and apolipoprotein B/A1 (APOR) ratios. This longitudinal observational study, using data from the Korean Genome and Epidemiology Study (KoGES), examined the rate of lung function decline, risk factors for the airflow obstruction (AFO), and the time to first AFO based on ALR and APOR groups. Among 5578 participants, high ALR and low APOR were associated with rapid decline in lung function and a shorter time to the first AFO. The high ALR group and the combined high ALR and low APOR group showed higher risk of experiencing AFO both at least once (RR 1.46, 95% CI 1.12–1.90; RR 1.74, 95% CI 1.23–2.46, respectively) and at the final follow up (RR 1.44, 95% CI 1.05–1.96; RR 1.72, 95% CI 1.14–2.60, respectively). High ALR and the combined high ALR and low APOR were identified as risk factors for earlier time to first AFO. This study highlights the potential of ALR and APOR as makers for predicting the risk of future airflow obstruction.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-024-80055-4. Introduction Chronic obstructive pulmonary disease (COPD) is a leading cause of chronic morbidity and mortality, accounting for about 6% of all deaths worldwide1. It is characterized by chronic lung inflammation and a progressive decline in lung function. COPD is also associated with systemic inflammation with increased levels of inflammatory markers such as C-reactive protein, fibrinogen, and the leukocyte count2. Although these markers are associated with the severity of COPD and increased risk of comorbidities in COPD, such as cardiovascular disease, pulmonary infections, depression, metabolic syndrome, and weight loss, there is a need for additional markers that reflect the lung function changes seen in COPD2,3. Adipose tissue is an active endocrine organ that secretes adipokines such as leptin and adiponectin. Leptin synthesis is correlated with the fat stores in the body and acts as a pro-inflammatory adipokine, affecting both innate and adaptive immune responses4–6. Leptin levels are elevated after food intake, in infection and inflammation, and in the obese5. Adiponectin has predominantly anti-inflammatory and antioxidative characteristics, and it protects against metabolic dysfunction related to obesity4. The leptin-to-adiponectin ratio (LAR) serves as a marker for dysfunctional adipose tissue, with a high ratio suggestive of an increased risk of metabolic syndrome6. However, studies have reported that systemic adiponectin levels are higher both in stable COPD and during acute exacerbations of COPD. Moreover, these levels are correlated with emphysema7–9. One study reported that a low leptin/adiponectin ratio was associated with a decline in lung function in patients with COPD, demonstrated in two cohorts10. Apolipoproteins are structural and functional components of the lipoprotein particles that transport cholesterol, triglycerides, and phospholipids between plasma and cells, maintaining normal lipid balance in the body11. Apolipoprotein B transfers cholesterol and triglycerides from their production sites to tissues, while apolipoprotein A1 reverses cholesterol transport out of cells and back to the liver11. The apolipoprotein B/A1 ratio is correlated with metabolic syndrome and the risk of cardiovascular disease12. Apolipoprotein A1, which has anti-inflammatory and antioxidant functions, may be related to the suppression of immune responses in allergic asthma and has been reported to protect against airflow obstruction (AFO) in asthma11. Another study showed that apolipoprotein A1 was positively correlated with the forced expiratory volume in 1 s (FEV1), while apolipoprotein B was negatively correlated with FEV113. This study investigated the associations of adipokines and apolipoproteins with the risk of future AFO. The adiponectin/leptin and apolipoprotein B/A1 ratios were assessed as potential biomarkers of lung function decline, including FEV1 and the forced vital capacity (FVC), and of the time to first AFO. Methods Ethics approval and consent to participate This study was conducted with bioresources from National Biobank of Korea, The Korea Disease Control and Prevention Agency, Republic of Korea (KBN-2023-005). Ethical approval was obtained from the Ethics Committee of Incheon St. Mary’s Hospital, and the institutional review board (IRB) number was OC23ZISI003. The requirement for informed consent was waived by the Ethics Committee of Incheon St. Mary’s Hospital. This study was conducted in accordance with the Declaration of Helsinki. Study population and enrollment criteria This was a longitudinal, observational community-based cohort study based on the Korean Genome and Epidemiology Study (KoGES), which collected data from people living in Ansan (urban) and Anseong (rural), Gyeonggi Province, South Korea. The study enrolled adults aged 40–69 years, collected demographic and clinical data from 2001 to 2002, and conducted follow-up investigations at 2-year intervals eight times until 2017–2018. In this study, we extracted data from baseline to the third follow-up (2007–2008), which included leptin, adiponectin, and apolipoprotein B and A1 levels. Clinical parameters At baseline and each follow-up assessment, demographic and socioeconomic data were collected, including age, sex, smoking habits, marriage status, and education and income levels. Anthropometric parameters obtained included height, weight, and waist and hip circumferences. Protocolized questionnaires were used to identify comorbidities (hypertension, diabetes mellitus, gastric ulcer, myocardial infarction, congestive heart failure, coronary heart disease, dyslipidemia, thyroid disease, asthma, COPD, peripheral vascular disease, kidney disease, cerebrovascular disease, and arthritis) and symptoms (modified Medical Research Council dyspnea scale scores, dyspnea, and chronic bronchitis symptoms). Lung function measurement Pulmonary function tests were performed at each visit by a trained technician using a standard spirometer (Vmax-2130; Sensor Medics, Yorba Linda, CA, USA). Calibration and quality control of the test were done regularly in accordance with guidelines14. Pre-bronchodilator values of FEV1 and FVC (in liters and percentage of the predicted value), the FEV1/FVC ratio, and forced expiratory flow between 25% and 75% of vital capacity (FEF25–75) were recorded. Laboratory data At baseline and each visit, the serum leptin, adiponectin, and apolipoprotein B and A1 levels were measured. For the adiponectin-to-leptin ratio (ALR), we used a cut-off value of 0.5 in accordance with previous studies15,16. The acceptable range of the apolipoprotein B/A1 ratio (APOR) differs according to sex: APOR < 0.77 for males and APOR < 0.63 for females are the optimal values regarding cardiovascular risk17. Thus, we defined APOR ≥ 0.77 and ≥ 0.63 as a high APOR for males and females, respectively. Statistical analysis Continuous variables are described as the mean and standard deviation and categorial variables as numbers and percentages. Baseline characteristics were compared using the chi-square test for categorical variables and Student’s t-test for continuous variables. Multivariate Poisson regression analyses were used to evaluate the risk of at least one occurrence of AFO, defined as FEV1/FVC < 0.7 over the study period and AFO at the final follow-up according to the ALR and APOR. All models were adjusted for age, sex, body mass index (BMI), smoking history, and FEV1 (%predicted). The differences in time to first AFO according to the ALR and APOR during the study period were estimated using survival analysis. Only subjects with no AFO at the initial survey were included in this analysis. Cox regression analysis was performed to obtain the hazard ratios (HRs) according to the ALR and APOR and time to first AFO. Adjusted variables included age, sex, BMI, smoking history, and FEV1 (%predicted). To evaluate the rate of lung function decline, changes in FEV1 and FVC over 6 years were assessed in a longitudinal analysis using a linear mixed model that examined the interactions of time with the ALR and APOR. Adjusted variables included age, sex, BMI, smoking history, and baseline FEV1 (%predicted). P-values < 0.05 were considered statistically significant. All statistical analyses were conducted using R.4.3.2 ver. (R Development Core Team, Vienna, Austria). Results Baseline characteristics of the study population Comparing the baseline characteristics of the 5578 subjects between the low (n = 1692) and high (n = 3886) ALR groups, the mean age was 57.3 ± 8.6 and 57.7 ± 8.5 years, respectively, and did not differ significantly. The low ALR group had more females, a higher BMI, greater waist and hip circumferences, greater proportion of never smokers, shorter smoking history, greater likelihood of being single, and lower education and income levels than the high ALR group (Table 1). Regarding the baseline pulmonary function, the low ALR group had a lower FVC (L) (3.1 ± 0.7 vs. 3.7 ± 0.8 L, p < 0.001), lower FVC (%predicted) (104.5 ± 12.5 vs. 108.6 ± 13.1, p < 0.001), lower FEV1 (L) (2.5 ± 0.5 vs. 2.9 ± 0.7 L, p < 0.001), and lower FEV1 (%predicted) (103.2 ± 13.5 vs. 104.3 ± 14.5, p = 0.011), but a higher FEV1/FVC ratio (80.6 ± 5.6 vs. 77.7 ± 7.2, p < 0.001) compared to the high ALR group. Table 1Baseline characteristics according to adiponectin/leptin ratio (ALR).Low (n = 1692)High (n = 3886)P-valueAge, years57.3 ± 8.657.7 ± 8.50.118Sex (female)1408 (83.2)1555 (40.0)< 0.001BMI26.6 ± 2.923.6 ± 2.6< 0.001Waist circumference (cm)88.1 ± 10.282.8 ± 9.0< 0.001Hip circumference (cm)95.0 ± 5.691.3 ± 4.9< 0.001Smoking history< 0.001 Never smoker1442 (85.2)2112 (54.4) Ex-smoker152 (9.0)959 (24.7) Current smoker98 (5.8)810 (20.9)Smoking, pack-year24.9 ± 18.928.5 ± 20.10.008Married (yes)1434 (84.8)3601 (92.7)< 0.001Education< 0.001 Elementary school or lower234 (27.8)309 (15.6) Middle or high school462 (54.8)1148 (58.0) University or above147 (17.4)522 (26.4)Income (10,000 won)0.016 < 200912 (55.5)1950 (51.4) 200–400452 (27.5)1103 (29.1) ≥ 400280 (17.0)739 (19.5)Area0.414 Anseong (rural)843 (49.8)1984 (51.1) Ansan (urban)849 (50.2)1902 (48.9)MMRC0.001 069 (19.1)171 (30.6) 1171 (47.4)227 (40.6) 215 (4.2)28 (5.0) 33 (0.8)8 (1.4) 4103 (28.5)125 (22.4)Dyspnea (yes)119 (7.0)148 (3.8)< 0.001Chronic bronchitis symptom (yes)90 (5.3)239 (6.2)0.247Comorbidities HTN88 (5.2)158 (4.1)0.070 DM46 (2.7)52 (1.3)< 0.001Gastric ulcer54 (3.2)137 (3.5)0.574 MI5 (0.3)9 (0.2)0.885 CHF1 (0.1)1 (0.0)1.000 CAD7 (0.4)21 (0.5)0.679 Dyslipidemia39 (2.3)52 (1.3)0.013 Thyroid disease15 (0.9)19 (0.5)0.118 Asthma5 (0.3)7 (0.2)0.591 COPD0 (0.0)4 (0.1)0.437 PVD1 (0.1)1 (0.0)1.000Kidney disease8 (0.5)8 (0.2)0.151 CVD12 (0.7)16 (0.4)0.217 Arthritis42 (2.5)45 (1.2)< 0.001Pulmonary function test FVC (L)3.1 ± 0.73.7 ± 0.8< 0.001 FVC (%pred)104.5 ± 12.5108.6 ± 13.1< 0.001 FEV1 (L)2.5 ± 0.52.9 ± 0.7< 0.001 FEV1 (%pred)103.2 ± 13.5104.3 ± 14.50.011 FEV1/FVC80.6 ± 5.677.7 ± 7.2< 0.001 FEF25-75 (L)2.7 ± 0.92.7 ± 1.10.096 FEF25-75 (%pred)101.6 ± 30.794.0 ± 31.9< 0.001BMI body mass index, MMRC modified Medical Research Council, HTN hypertension, DM diabetes mellitus, MI myocardial infarction, CHF congestive heart failure, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, PVD peripheral vascular disease, CVD cerebrovascular disease, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, FEF25–75 forced expiratory flow between 25% and 75% of vital capacity. Table 1Baseline characteristics according to adiponectin/leptin ratio (ALR).Low (n = 1692)High (n = 3886)P-valueAge, years57.3 ± 8.657.7 ± 8.50.118Sex (female)1408 (83.2)1555 (40.0)< 0.001BMI26.6 ± 2.923.6 ± 2.6< 0.001Waist circumference (cm)88.1 ± 10.282.8 ± 9.0< 0.001Hip circumference (cm)95.0 ± 5.691.3 ± 4.9< 0.001Smoking history< 0.001 Never smoker1442 (85.2)2112 (54.4) Ex-smoker152 (9.0)959 (24.7) Current smoker98 (5.8)810 (20.9)Smoking, pack-year24.9 ± 18.928.5 ± 20.10.008Married (yes)1434 (84.8)3601 (92.7)< 0.001Education< 0.001 Elementary school or lower234 (27.8)309 (15.6) Middle or high school462 (54.8)1148 (58.0) University or above147 (17.4)522 (26.4)Income (10,000 won)0.016 < 200912 (55.5)1950 (51.4) 200–400452 (27.5)1103 (29.1) ≥ 400280 (17.0)739 (19.5)Area0.414 Anseong (rural)843 (49.8)1984 (51.1) Ansan (urban)849 (50.2)1902 (48.9)MMRC0.001 069 (19.1)171 (30.6) 1171 (47.4)227 (40.6) 215 (4.2)28 (5.0) 33 (0.8)8 (1.4) 4103 (28.5)125 (22.4)Dyspnea (yes)119 (7.0)148 (3.8)< 0.001Chronic bronchitis symptom (yes)90 (5.3)239 (6.2)0.247Comorbidities HTN88 (5.2)158 (4.1)0.070 DM46 (2.7)52 (1.3)< 0.001Gastric ulcer54 (3.2)137 (3.5)0.574 MI5 (0.3)9 (0.2)0.885 CHF1 (0.1)1 (0.0)1.000 CAD7 (0.4)21 (0.5)0.679 Dyslipidemia39 (2.3)52 (1.3)0.013 Thyroid disease15 (0.9)19 (0.5)0.118 Asthma5 (0.3)7 (0.2)0.591 COPD0 (0.0)4 (0.1)0.437 PVD1 (0.1)1 (0.0)1.000Kidney disease8 (0.5)8 (0.2)0.151 CVD12 (0.7)16 (0.4)0.217 Arthritis42 (2.5)45 (1.2)< 0.001Pulmonary function test FVC (L)3.1 ± 0.73.7 ± 0.8< 0.001 FVC (%pred)104.5 ± 12.5108.6 ± 13.1< 0.001 FEV1 (L)2.5 ± 0.52.9 ± 0.7< 0.001 FEV1 (%pred)103.2 ± 13.5104.3 ± 14.50.011 FEV1/FVC80.6 ± 5.677.7 ± 7.2< 0.001 FEF25-75 (L)2.7 ± 0.92.7 ± 1.10.096 FEF25-75 (%pred)101.6 ± 30.794.0 ± 31.9< 0.001BMI body mass index, MMRC modified Medical Research Council, HTN hypertension, DM diabetes mellitus, MI myocardial infarction, CHF congestive heart failure, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, PVD peripheral vascular disease, CVD cerebrovascular disease, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, FEF25–75 forced expiratory flow between 25% and 75% of vital capacity. Baseline characteristics according to adiponectin/leptin ratio (ALR). BMI body mass index, MMRC modified Medical Research Council, HTN hypertension, DM diabetes mellitus, MI myocardial infarction, CHF congestive heart failure, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, PVD peripheral vascular disease, CVD cerebrovascular disease, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, FEF25–75 forced expiratory flow between 25% and 75% of vital capacity. Considering the APOR, the high APOR group (n = 3221) was older (58.1 ± 8.4 vs. 56.9 ± 8.6 years, p < 0.001) and had more females, a higher BMI, a larger proportion of never smokers (although the amount smoked did not differ significantly), lower education and income levels, and a higher rate of unmarried status than the low APOR group (n = 2357) (Table 2). Comparing pulmonary function, the high APOR group had a lower FVC (L) (3.4 ± 0.8 vs. 3.7 ± 0.8 L, p < 0.001), lower FEV1 (L) (2.6 ± 0.6 vs. 2.9 ± 0.7 L, p < 0.001), higher FEV1 (%predicted) (104.3 ± 13.9 vs. 103.5 ± 14.5, p = 0.040), and higher FEV1/FVC ratio (79.0 ± 6.6 vs. 78.0 ± 7.3, p < 0.001) than the low APOR group. Table 2Baseline characteristics according to apolipoprotein B/A1 ratio (APOR).Low (n = 2357)High (n = 3221)P-valueAge, years56.9 ± 8.658.1 ± 8.4< 0.001Sex (female)913 (38.7)2050 (63.6)< 0.001BMI23.9 ± 3.125.0 ± 2.9< 0.001Waist circumference (cm)83.3 ± 9.885.2 ± 9.6< 0.001Hip circumference (cm)91.9 ± 5.592.8 ± 5.2< 0.001Smoking history< 0.001 Never smoker1266 (53.7)2288 (71.1) Ex-smoker626 (26.6)485 (15.1) Current smoker464 (19.7)444 (13.8)Smoking, pack-year27.6 ± 19.528.5 ± 20.50.323Married (yes)2196 (93.2)2839 (88.2)< 0.001Education< 0.001 Elementary school or lower161 (13.5)382 (23.5) Middle or high school696 (58.2)914 (56.2) University or above338 (28.3)331 (20.3)Income (10,000 won)< 0.001 < 2001128 (49.0)1734 (55.3) 200–400691 (30.0)864 (27.6) ≥ 400483 (21.0)536 (17.1)Area0.959 Anseong (rural)1196 (50.7)1631 (50.6) Ansan (urban)1161 (49.3)1590 (49.4)MMRC0.223 0106 (30.3)134 (23.5) 1146 (41.7)252 (44.2) 215 (4.3)28 (4.9) 33 (0.9)8 (1.4) 480 (22.9)148 (26.0)Dyspnea (yes)93 (3.9)174 (5.4)0.014Chronic bronchitis symptom (yes)136 (5.8)193 (6.0)0.768Comorbidities HTN98 (4.2)148 (4.6)0.469 DM36 (1.5)62 (1.9)0.309 Gastric ulcer73 (3.1)118 (3.7)0.280 MI6 (0.3)8 (0.2)1.000 CHF1 (0.0)1 (0.0)1.000 CAD13 (0.6)15 (0.5)0.799 Dyslipidemia42 (1.8)49 (1.5)0.517 Thyroid disease10 (0.4)24 (0.7)0.177 Asthma8 (0.3)4 (0.1)0.156 COPD3 (0.1)1 (0.0)0.413 PVD1 (0.0)1 (0.0)1.000 Kidney disease8 (0.3)8 (0.2)0.709 CVD13 (0.6)15 (0.5)0.799 Arthritis32 (1.4)55 (1.7)0.349Pulmonary function test FVC (L)3.7 ± 0.83.4 ± 0.8< 0.001 FVC (%pred)107.6 ± 13.2107.3 ± 12.90.395 FEV1 (L)2.9 ± 0.72.6 ± 0.6< 0.001 FEV1 (%pred)103.5 ± 14.5104.3 ± 13.90.040 FEV1/FVC78.0 ± 7.379.0 ± 6.6< 0.001 FEF25–75 (L)2.8 ± 1.12.7 ± 1.00.001 FEF25–75 (%pred)93.8 ± 31.398.1 ± 31.8< 0.001BMI body mass index, MMRC modified Medical Research Council, HTN hypertension, DM diabetes mellitus, MI myocardial infarction, CHF congestive heart failure, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, PVD peripheral vascular disease, CVD cerebrovascular disease, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, FEF25–75 forced expiratory flow between 25% and 75% of vital capacity. Table 2Baseline characteristics according to apolipoprotein B/A1 ratio (APOR).Low (n = 2357)High (n = 3221)P-valueAge, years56.9 ± 8.658.1 ± 8.4< 0.001Sex (female)913 (38.7)2050 (63.6)< 0.001BMI23.9 ± 3.125.0 ± 2.9< 0.001Waist circumference (cm)83.3 ± 9.885.2 ± 9.6< 0.001Hip circumference (cm)91.9 ± 5.592.8 ± 5.2< 0.001Smoking history< 0.001 Never smoker1266 (53.7)2288 (71.1) Ex-smoker626 (26.6)485 (15.1) Current smoker464 (19.7)444 (13.8)Smoking, pack-year27.6 ± 19.528.5 ± 20.50.323Married (yes)2196 (93.2)2839 (88.2)< 0.001Education< 0.001 Elementary school or lower161 (13.5)382 (23.5) Middle or high school696 (58.2)914 (56.2) University or above338 (28.3)331 (20.3)Income (10,000 won)< 0.001 < 2001128 (49.0)1734 (55.3) 200–400691 (30.0)864 (27.6) ≥ 400483 (21.0)536 (17.1)Area0.959 Anseong (rural)1196 (50.7)1631 (50.6) Ansan (urban)1161 (49.3)1590 (49.4)MMRC0.223 0106 (30.3)134 (23.5) 1146 (41.7)252 (44.2) 215 (4.3)28 (4.9) 33 (0.9)8 (1.4) 480 (22.9)148 (26.0)Dyspnea (yes)93 (3.9)174 (5.4)0.014Chronic bronchitis symptom (yes)136 (5.8)193 (6.0)0.768Comorbidities HTN98 (4.2)148 (4.6)0.469 DM36 (1.5)62 (1.9)0.309 Gastric ulcer73 (3.1)118 (3.7)0.280 MI6 (0.3)8 (0.2)1.000 CHF1 (0.0)1 (0.0)1.000 CAD13 (0.6)15 (0.5)0.799 Dyslipidemia42 (1.8)49 (1.5)0.517 Thyroid disease10 (0.4)24 (0.7)0.177 Asthma8 (0.3)4 (0.1)0.156 COPD3 (0.1)1 (0.0)0.413 PVD1 (0.0)1 (0.0)1.000 Kidney disease8 (0.3)8 (0.2)0.709 CVD13 (0.6)15 (0.5)0.799 Arthritis32 (1.4)55 (1.7)0.349Pulmonary function test FVC (L)3.7 ± 0.83.4 ± 0.8< 0.001 FVC (%pred)107.6 ± 13.2107.3 ± 12.90.395 FEV1 (L)2.9 ± 0.72.6 ± 0.6< 0.001 FEV1 (%pred)103.5 ± 14.5104.3 ± 13.90.040 FEV1/FVC78.0 ± 7.379.0 ± 6.6< 0.001 FEF25–75 (L)2.8 ± 1.12.7 ± 1.00.001 FEF25–75 (%pred)93.8 ± 31.398.1 ± 31.8< 0.001BMI body mass index, MMRC modified Medical Research Council, HTN hypertension, DM diabetes mellitus, MI myocardial infarction, CHF congestive heart failure, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, PVD peripheral vascular disease, CVD cerebrovascular disease, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, FEF25–75 forced expiratory flow between 25% and 75% of vital capacity. Baseline characteristics according to apolipoprotein B/A1 ratio (APOR). BMI body mass index, MMRC modified Medical Research Council, HTN hypertension, DM diabetes mellitus, MI myocardial infarction, CHF congestive heart failure, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, PVD peripheral vascular disease, CVD cerebrovascular disease, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, FEF25–75 forced expiratory flow between 25% and 75% of vital capacity. Lung function decline rate The rate of lung function decline differed significantly between the ALR and APOR groups at 2, 4, and 6 years after the baseline tests. The high ALR group had a higher baseline FEV1 and FVC, and showed significantly more rapid declines in both, than the low ALR group (–48.6 vs. − 38.6 mL/year, p < 0.001 for FEV1, and − 38.3 vs. − 31.8 mL/year, p < 0.001 for FVC, respectively; Fig. 1). The low APOR group had a higher baseline FEV1 and FVC, and both declined more rapidly than in the high APOR group (– 48.9 vs. − 42.9 mL/year, p < 0.001 for FEV1, and − 38.1 vs. − 34.8 mL/year, p < 0.001 for FVC, respectively; Fig. 2). Fig. 1Lung function decline rate according to ALR. Adjusted variables: age, sex, BMI, smoking history, FEV1 (%). ALR adiponectin-to-leptin ratio, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, BMI body mass index. Lung function decline rate according to ALR. Adjusted variables: age, sex, BMI, smoking history, FEV1 (%). ALR adiponectin-to-leptin ratio, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, BMI body mass index. Fig. 2Lung function decline rate according to APOR. Adjusted variables: age, sex, BMI, smoking history, FEV1 (%). APOR apolipoprotein B-to-A1 ratio, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, BMI body mass index. Lung function decline rate according to APOR. Adjusted variables: age, sex, BMI, smoking history, FEV1 (%). APOR apolipoprotein B-to-A1 ratio, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, BMI body mass index. Risk factors for the occurrence of AFO The risk factors for the occurrence of AFO at least once during follow-up and at the final follow-up (year 6) were evaluated. In the multivariate analysis, a high ALR was significantly associated with an increased risk of AFO at least once and at year 6 compared to a low ALR (Table 3; relative risk [RR] 1.46, 95% confidence interval [CI] [1.12–1.90], p = 0.010, and RR 1.44, 95% CI [1.05–1.96], p = 0.035, respectively). The APOR did not show a significant association with the risk of AFO, either at least once or at year 6. The subjects with a combined high ALR and low APOR were more likely to be diagnosed with AFO, both at least once and at year 6, than those with a combined low ALR and high APOR (RR 1.74, 95% CI [1.23–2.46], p = 0.004, and RR 1.72, 95% CI [1.14–2.60], p = 0.015, respectively). Table 3Multivariable Poisson regression analysis for occurrence of airflow obstruction (AFO).ALR high, vs. lowAPOR high, vs. lowALR high and APOR low, vs. ALR low & APOR highRR95% CIP-valueRR95% CIP-valueRR95% CIP-valueAt least one AFO1.461.12–1.900.0100.870.73–1.030.1521.741.23–2.460.004AFO at year 61.441.05–1.960.0350.860.70–1.050.1761.721.14–2.600.015Adjusted variables include age, sex, BMI and smoking history, FEV1 (%).ALR adiponectin-to-leptin ratio, APOR apolipoprotein B-to-A1 ratio, AFO airflow obstruction, RR relative risk, CI confidence interval, BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity. Table 3Multivariable Poisson regression analysis for occurrence of airflow obstruction (AFO).ALR high, vs. lowAPOR high, vs. lowALR high and APOR low, vs. ALR low & APOR highRR95% CIP-valueRR95% CIP-valueRR95% CIP-valueAt least one AFO1.461.12–1.900.0100.870.73–1.030.1521.741.23–2.460.004AFO at year 61.441.05–1.960.0350.860.70–1.050.1761.721.14–2.600.015Adjusted variables include age, sex, BMI and smoking history, FEV1 (%).ALR adiponectin-to-leptin ratio, APOR apolipoprotein B-to-A1 ratio, AFO airflow obstruction, RR relative risk, CI confidence interval, BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity. Multivariable Poisson regression analysis for occurrence of airflow obstruction (AFO). Adjusted variables include age, sex, BMI and smoking history, FEV1 (%). ALR adiponectin-to-leptin ratio, APOR apolipoprotein B-to-A1 ratio, AFO airflow obstruction, RR relative risk, CI confidence interval, BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity. Time to first AFO Of the 6062 participants with baseline pulmonary function test results, the analysis included 5476 without AFO at the initial survey. In the survival analysis of the time to first AFO, the high ALR group reached AFO significantly sooner than the low ALR group (Fig. 3A; p < 0.001). Likewise, the low APOR group experienced AFO significantly sooner than the high APOR group (Fig. 3B; p < 0.001). In the Cox regression, older age, male sex, lower BMI, ex- or current smoker status, low FEV1, high FVC, and high ALR were associated with a shorter time to first AFO in the univariate analyses. In the multivariate analysis, high ALR was significantly associated with a shorter time to first AFO (Table 4; HR 1.52, 95% CI [1.14–2.01], p = 0.004). In the multivariate model combining ALR and APOR, the combined high ALR and low APOR group had a significantly shorter time to first AFO than the combined low ALR and high APOR group (HR 1.85, 95% CI [1.27–2.68], p = 0.001). Fig. 3Time to first airflow obstruction (AFO). ALR adiponectin-to-leptin ratio, APOR apolipoprotein B-to-A1 ratio. Time to first airflow obstruction (AFO). ALR adiponectin-to-leptin ratio, APOR apolipoprotein B-to-A1 ratio. Table 4Cox regression analysis for time to first airflow obstruction.VariablesMultivariableHR95% CIP-valueALR, high1.521.14–2.010.004APOR, high0.860.79–1.030.108ALR high and APOR low, vs. ALR low and APOR high1.851.27–2.680.001Adjusted variables include age, sex, BMI, smoking history, FEV1 (%).ALR adiponectin-to-leptin ratio, APOR apolipoprotein B-to-A1 ratio, AFO airflow obstruction, HR hazard ratio, CI confidence interval, BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity. Table 4Cox regression analysis for time to first airflow obstruction.VariablesMultivariableHR95% CIP-valueALR, high1.521.14–2.010.004APOR, high0.860.79–1.030.108ALR high and APOR low, vs. ALR low and APOR high1.851.27–2.680.001Adjusted variables include age, sex, BMI, smoking history, FEV1 (%).ALR adiponectin-to-leptin ratio, APOR apolipoprotein B-to-A1 ratio, AFO airflow obstruction, HR hazard ratio, CI confidence interval, BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity. Cox regression analysis for time to first airflow obstruction. Adjusted variables include age, sex, BMI, smoking history, FEV1 (%). ALR adiponectin-to-leptin ratio, APOR apolipoprotein B-to-A1 ratio, AFO airflow obstruction, HR hazard ratio, CI confidence interval, BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity. Discussion The high ALR and low APOR groups in this study both had a higher initial FEV1 and FVC, associated with more rapid declines in lung function over the 6-year follow-up. These groups also experienced the first AFO significantly sooner. The high ALR group and the combined high ALR and low APOR group had increased risks of AFO at least once and at year 6. A high ALR, and combined high ALR and low APOR were revealed as risk factors for a shorter time to first AFO. Several studies have investigated the associations of LAR with lung function in COPD. Suzuki et al. reported that a low LAR was associated with lung function decline in COPD, consistent with our results10. The patients with rapid declines in lung function had a lower plasma LAR than those with a slow or sustained decline in lung function. Conversely, Oh et al. reported that the plasma LAR was inversely correlated with the initial FEV1 (% and L), and was significantly associated with the progression of computed tomography (CT)-assessed emphysema over 3 years3. Adiponectin and leptin both regulate inflammation in the lungs and changes in lung function. Adiponectin is an anti-inflammatory adipokine that exerts pro-inflammatory effects under some conditions5. The adiponectin receptor is expressed in multiple cell types in the lung, and adiponectin has a pro-inflammatory effect on airway epithelial cells. Therefore, adiponectin is related to local lung inflammation. As COPD is a chronic inflammatory disease, adiponectin levels are increased in patients with COPD, and the expression of its receptor is also increased in airway epithelial cells. Previous studies reported elevated serum adiponectin levels in males with COPD, and this was associated with body weight loss, hyperinflation, and systemic inflammation7,8,18. In ever-smokers with or without COPD, serum adiponectin was inversely correlated with FEV1 (% predicted) after adjusting for age, BMI, and smoking status. Serum adiponectin was negatively associated with lung function in patients with COPD but positively associated in the healthy population7. By contrast, in another study, serum adiponectin levels in the stable COPD group were not correlated with the FEV1, FEV1/FVC, dyspnea score, BMI, or any inflammatory parameters8. In the COPDGene cohort study, higher serum adiponectin was independently associated with CT-assessed emphysema and less bronchodilator responsiveness after adjusting for age, sex, and BMI9. This concurs with a mouse study in which adiponectin knockout mice showed a significant decrease in smoke-induced emphysema and airway inflammation19. These findings suggest that adiponectin contributes to the development of emphysema. Leptin is mainly a pro-inflammatory adipokine that has an important role in the inflammatory process in the lung. Leptin and its receptor are expressed by human lung bronchial and alveolar epithelial cells; therefore, the lung is a probable target organ in leptin signaling5,20. Leptin is involved in lung development and the maturation of fetal lungs. It acts as a mediator of the lung maturation effect of glucocorticoids, plays a crucial role in postnatal lung remodeling, and regulates lung homeostasis via the control of lung ventilation. Leptin also increases bronchial diameter regardless of BMI, and its role in the immune response contributes to pulmonary defense against damage, such as that caused by infections20. In laboratory studies, mice with leptin signaling pathway defects recruited more neutrophils to lung tissue on exposure to cigarette smoke, and recruited fewer CD4 + and CD8 + cells than wild-type mice. This suggests that activation of the leptin receptor plays an important role in the smoke-induced inflammatory response in the lung21. In vivo and in vitro studies demonstrate that exposure to cigarette smoke can increase leptin expression in bronchial epithelial cells, although another study reported lower expression of the leptin receptor in the bronchial epithelial cells of smokers with or without COPD compared to never-smokers21–23. Thus, the associations of serum leptin and smoking with COPD prevalence remain controversial. Most studies suggest that apolipoprotein A1 exerts a protective effect on lung function, as it has anti-inflammatory and antioxidant effects that reduce the severity of respiratory diseases11,24. Apolipoprotein A1 levels were decreased in the lungs of patients with COPD and mice exposed to cigarette smoke25. Sputum apolipoprotein A1 levels were also reduced in smokers with COPD compared to healthy smokers26. These results suggest that apolipoprotein A1 has a protective effect in smoking-induced emphysema and airflow limitation. By contrast, apolipoprotein B has a negative effect on lung function, although most of the studies were conducted in patients with asthma; apolipoprotein B levels were associated with more severe AFO and a low FEV1 (%) in these patients27,28. This association was also observed in a study of the general population13. Few studies have investigated the association between the apolipoprotein B/A1 ratio and lung function. In a recent cross-sectional cohort study of healthy Koreans, a high apolipoprotein B/A1 ratio was associated with reduced lung function29. A high serum leptin level also signifies leptin resistance in obesity. While obesity is related to a higher risk of cardiovascular diseases and respiratory complications, such as COPD, asthma, and obstructive sleep apnea, obese patients with chronic illness or respiratory diseases have a better prognosis than normal-weight patients with the same disease. This phenomenon is known as the “obesity paradox”20, which was first described by Gruberg et al. in 200230. Regarding the association with COPD, several studies have reported that although COPD patients with a higher BMI experience more respiratory symptoms and limitations in activity, they have more favorable prognoses than patients with a normal BMI. In large retrospective studies, overweight/obese patients with COPD had lower in-hospital mortality than normal-weight patients31–33. Lower COPD mortality was also observed in a prospective study and meta-analysis34–36. However, a study that analyzed cohorts from the National Health and Nutrition Examination Survey (NHANES) showed that overweight/obese patients in the smoking COPD group had a lower mortality rate than normal-weight patients, while this association was not observed in the nonsmoking COPD group, suggesting that the obesity paradox applies only to smoking-induced COPD37. The normal range and cut-off value for ALR varies across studies. In the context of cardiometabolic risk, an ALR > 1.0 (with adiponectin measured in µg/mL and leptin in ng/mL) has been regarded as normal, while ALR < 0.5 is associated with an increased cardiometabolic risk15. Another study described LAR < 0.5 as normal, with higher values suggesting increased cardiovascular risk16. We defined an ALR < 0.5 as low and an ALR ≥ 0.5 as high. The decline rates of FEV1 were − 48.6 ml/year and − 38.6 ml/year in high and low ALR group, and − 42.9 ml/year and − 48.9 ml/year in high and low APOR group. While these differences are statistically significant, they are below the commonly accepted minimal clinically important difference (MCID)38. However, given that these values are derived from a general population with less severe airflow limitation than a typical COPD cohort, even smaller differences could be clinically meaningful in this context. This study is meaningful as it conducted a longitudinal analysis over 6 years. We found an association in the general population between lipid profile biomarkers and lung function after adjusting for confounding factors. Furthermore, while most previous studies focused only on the ALR or the apolipoprotein B/A1 ratio, we examined both together. This study has several limitations. First, as the study cohort consisted of middle-aged subjects from two cities in northeast Asia, there may be limitations regarding generalizability. Further studies with other ethnic groups are required. Second, the database did not include a post-bronchodilator value, which is usually required for defining AFO. However, from a longitudinal perspective, there is evidence that pre-bronchodilator values can be instrumental in evaluating COPD patients39. Additionally, numerous studies have used pre-bronchodilator values as an alternative to post-bronchodilator measurements40–42. Finally, one limitation of this study is the presence of interval-censored data, for which Cox proportional hazards regression and Kaplan-Meier curves may not be fully appropriate. While these methods assume exact event times, the interval-censoring in our data could introduce some bias, and this should be considered when interpreting the results. Conclusions Our study demonstrated that a high ALR and low APOR are associated with a rapid decline in lung function. Furthermore, a high ALR and combination of high ALR and low APOR increases the risk of future AFO. These findings suggest that ALR and APOR are valuable for predicting the risk of future AFO. Using these biomarkers in clinical practice may improve the early detection and management of COPD. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1